rxstat › Shortages › Fosaprepitant

Fosaprepitant (Emend) shortage status

Shortage anticipated

Source: Health Canada shortage reports · Updated Aug 12, 2026

A shortage of Fosaprepitant is anticipated but not yet confirmed. 1 product(s) have anticipated-shortage reports on file with Health Canada.

An intravenous anti-nausea medication used to prevent nausea and vomiting caused by chemotherapy.

Products affected
0 / 1
Reports on file
7

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Anticipated
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Aug 11, 2026 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Jun 3, 2026 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Feb 16, 2026 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Sep 23, 2024 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Apr 19, 2022 · Demand increase for the drug.
Resolved
EMEND IV
150MG · POWDER FOR SOLUTION · MERCK CANADA INC
DIN 02363356 · ended Aug 30, 2021 · Demand increase for the drug.

What's happening

A manufacturer has told Health Canada it expects supply of Fosaprepitant to fall short of demand. Anticipated shortages sometimes resolve without patients noticing; this page updates as soon as the status changes.

Fosaprepitant is classified under “ANTIEMETICS AND ANTINAUSEANTS” (ATC A04AD).

Recent changes

Common questions

What is Fosaprepitant used for?

An intravenous anti-nausea medication used to prevent nausea and vomiting caused by chemotherapy.

When will Fosaprepitant be back in stock in Canada?

Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.

Why is Fosaprepitant in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (antiemetics and antinauseants)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Nabilone (Cesamet) No current shortage Granisetron Partial shortage 1 of 2 reported products affected Ondansetron (Zofran) Partial shortage 12 of 55 reported products affected · est. return Oct 30, 2026 Palonosetron (Aloxi) Partial shortage 1 of 2 reported products affected Aprepitant (Emend) Discontinued 0 of 2 reported products affected Aprepitant (Emend Tri-Pack) Discontinued 0 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.